TOP TEN perturbations for 39640_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39640_at
Selected probe(set): 205100_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39640_at (205100_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):4.916198Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.8089695Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):-4.7741537Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):4.723418Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):-4.6984663Number of Samples:2 / 3
Experimental | glioma study 16 (LN-18) |
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):4.535928Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):-4.4661407Number of Samples:13 / 2
Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.3769007Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):-4.298689Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):4.2042494Number of Samples:5 / 7
Experimental | E. coli study 2 |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
Control | unstimulated, normal monocyte-derived macrophage sample |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |